Biological mesh

PreclinicalBiologic

UUniversity Hospital, Lille

Biological mesh is one of 4 biologic programs targeting Intracerebral Haemorrhage. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intracerebral HaemorrhageRecruiting

Intracerebral HaemorrhagePreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Intracerebral Haemorrhage

#DrugCompanyPhaseTrials

Cyklokapron

JJ Molner

Approved

1 2

Eliquis

Bristol-Myers Squibb

Phase 3

1 3

Bayer Aspirin

Bayer

Phase 3

1 4

Biological mesh

UUniversity Hospital, Lille

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intracerebral Haemorrhage1 trial

Influence of Cerebral Oedema in Intracerebral Haemorrhage

Recruiting·UUniversity Hospital, Lille·N/A·NCT04621357·500 enrolled

Randomized Controlled Trial1 trial

Biological Meshes in Infected Fields: a Randomized Controlled Trial

Completed·UUniversity Hospital, Lille·Phase 3·NCT01594450·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Biological mesh. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biological mesh compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biological mesh. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Lille company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Lille

Biological mesh

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Intracerebral Haemorrhage1 trial

Randomized Controlled Trial1 trial

References

Drug Info

Quick Facts

Related News